| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 31, 2002
From the Department of Neuroscience (K.H., Y.O., W.N., K.S.) and the Department of Surgery and Clinical Oncology (M.Y., M.M.), Osaka University Graduate School of Medicine, Osaka, Japan; the Department of Cardiovascular Medicine, Hokkaido University, Graduate School of Medicine (M.T., A.K.), Sapporo, Japan; the Department of Neurosurgery, Iwate Medical University School of Medicine (K.Y., A.O.), Morioka, Japan; and the Molecular Biology Laboratory, Medical Research Laboratories, Taisho Pharmaceutical Co, Ltd (T.K.), Saitama, Japan. * To whom correspondence should be addressed. E-mail: sobue{at}nbiochem.med.osaka-u.ac.jp.
Background--The coordinated activation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (p38MAPK) is critical for the induction of vascular and visceral smooth muscle cell (SMC) dedifferentiation. We previously reported that on the forced activation of both MAPKs, visceral SMCs secrete a non-heparin-binding protein factor(s) that is involved in the dedifferentiation of neighboring SMCs. In this study, we sought to identify the dedifferentiation factor(s) derived from vascular SMCs (VSMCs). Methods and Results--We fractionated the VSMC dedifferentiation factor(s) in the conditioned medium obtained from differentiated VSMCs in which both ERK and p38MAPK were forcedly activated and identified epiregulin as a major autocrine/paracrine factor for VSMC dedifferentiation. The epiregulin-induced VSMC dedifferentiation was mediated through the coordinated activation of ERK and p38MAPK. Unsaturated lysophosphatidic acid and platelet-derived growth factor-BB, which are potent VSMC dedifferentiation factors, rapidly upregulated epiregulin mRNA expression in an ERK- and p38MAPK-dependent manner. Reverse transcriptase-polymerase chain reaction and/or immunohistological analyses revealed the restricted expression of epiregulin in human atherosclerotic and balloon-injured rat arteries, in which the phenotypic modulation of medial VSMCs occurred in vivo. Conclusions--Epiregulin is released from VSMCs primed by atherogenic factors and acts as a major autocrine/paracrine factor for VSMC dedifferentiation. It may be involved in the progression of vascular remodeling such as atherosclerosis.
Revised on July 18, 2003
Accepted on July 21, 2003
Epiregulin as a Major Autocrine/Paracrine Factor Released From ERK- and p38MAPK-Activated Vascular Smooth Muscle Cells
Masanori Takahashi MD,
This article has been cited by other articles:
![]() |
G. E. White, T. C.C. Tan, A. E. John, C. Whatling, W. L. McPheat, and D. R. Greaves Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling Cardiovasc Res, November 12, 2009; (2009) cvp341v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Wakamatsu, J. B. Collins, J. S. Parker, M. Tessema, N. P. Clayton, T.-V. T. Ton, H.-H. L. Hong, S. Belinsky, T. R. Devereux, R. C. Sills, et al. Gene Expression Studies Demonstrate that the K-ras/Erk MAP Kinase Signal Transduction Pathway and Other Novel Pathways Contribute to the Pathogenesis of Cumene-induced Lung Tumors Toxicol Pathol, July 1, 2008; 36(5): 743 - 752. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Cornish, B. J. Hurtgen, K. McInnerney, N. L. Burritt, R. M. Taylor, J. N. Jarvis, S. Y. Wang, and J. B. Burritt Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Independent Resistance to Aspergillus fumigatus in Alveolar Macrophages J. Immunol., May 15, 2008; 180(10): 6854 - 6867. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Li, F. Takeuchi, J.-a. Wang, Q. Fan, T. Komurasaki, E. M. Billings, G. Pacheco-Rodriguez, J. Moss, and T. N. Darling Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas PNAS, March 4, 2008; 105(9): 3539 - 3544. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Airoldi, E. Di Carlo, C. Cocco, G. Taverniti, T. D'Antuono, E. Ognio, M. Watanabe, D. Ribatti, and V. Pistoia From the Cover: Endogenous IL-12 triggers an antiangiogenic program in melanoma cells PNAS, March 6, 2007; 104(10): 3996 - 4001. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Patel, D. J. Kim, J. M. Peters, and G. H. Perdew The Aryl Hydrocarbon Receptor Directly Regulates Expression of the Potent Mitogen Epiregulin Toxicol. Sci., January 1, 2006; 89(1): 75 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Zhuang, Y. Yan, J. Han, and R. G. Schnellmann p38 Kinase-mediated Transactivation of the Epidermal Growth Factor Receptor Is Required for Dedifferentiation of Renal Epithelial Cells after Oxidant Injury J. Biol. Chem., June 3, 2005; 280(22): 21036 - 21042. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hayashi, K. Shibata, T. Morita, K. Iwasaki, M. Watanabe, and K. Sobue Insulin Receptor Substrate-1/SHP-2 Interaction, a Phenotype-dependent Switching Machinery of Insulin-like Growth Factor-I Signaling in Vascular Smooth Muscle Cells J. Biol. Chem., September 24, 2004; 279(39): 40807 - 40818. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shirasawa, S. Sugiyama, I. Baba, J. Inokuchi, S. Sekine, K. Ogino, Y. Kawamura, T. Dohi, M. Fujimoto, and T. Sasazuki Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage PNAS, September 21, 2004; 101(38): 13921 - 13926. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |